The ABCs of Pharmacogenomics in Clinical Practice

Slides:

Advertisements

Similar presentations

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

Advertisements

New Horizons for SMA.

Primary Care Challenges in Depression - To Treat or Refer?

Why New Treatments for Schizophrenia Should Be on Your Radar

Improving Survival in Glioblastoma Multiforme

Pharmaceutical- vs Dispensary-Sourced Cannabinoids

Updates on Emerging GLP-1 Receptor Agonists

This program will include a discussion of off-label treatment and devices and investigational agents and devices not approved by the FDA for use in the.

Applying New Data in Practice:

Progression After Cancer Immunotherapy in Advanced NSCLC

Immune Reconstitution in MS:

The HCV Revolution: Are You and Your Practice Ready?

Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update

New Standards of Care in ALK-Translocated Advanced NSCLC

Unmet Needs in Schizophrenia

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

The Mood Disorder Spectrum

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

The Evolving Role of Immunotherapy in NSCLC

Updates in Detection and Management of BCRPC

Individualizing Care in Ovarian Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

Postpartum Depression

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Managing Depression is a Team Effort:

Case Studies in Unresectable Hepatocellular Carcinoma

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

Impactful Data in TD That Can Guide Treatment Decisions

New Data on Emerging Treatments for Psoriasis

How to Select Therapy In Newly Diagnosed CLL

Advancing Care Across the Spectrum of Pancreatic Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Updates in the Management of Acute Promyelocytic Leukemia

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Immune Checkpoint Inhibitors in Lung Cancer

Tackling Schizophrenia With Your Patients

Guide to Atopic Dermatitis

Clinical Pearls on Hot Topics in MS

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

The Rising Cost of Healthcare and Potential Impact of Biosimilars

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Patient Questions and Expert Answers in Psoriasis:

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

The Psychiatrist's Role in Tardive Dyskinesia

Patient and Clinician Perspectives on Preventive Therapy for Migraine

New Trends in Treatment for Major Depressive Disorder

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a.

Peanut Allergy Immunotherapy

The Role of Measurable Residual Disease in AML

Case Studies in Locally Advanced Pancreatic Cancer

The Psychiatrist's Role in Tardive Dyskinesia

New Paradigms in M0 CRPC.

Peanut Allergy Immunotherapy

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

VKA Reversal and LVADs.

CDK4/6 Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Binge Eating Disorder.

The Glutamate Pathway.

Next-Generation Sequencing and ctDNA

Immune Checkpoint Inhibitors in Lung Cancer

Presentation transcript:

The ABCs of Pharmacogenomics in Clinical Practice

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Unmet Needs in the Treatment of MDD

What Is Pharmacogenomics/Pharmacogenetics (PGx)?

PGx Testing in Psychiatry

Using PGx Testing to Select MDD Treatment Meta-Analysis of Studies

GUIDED Trial of PGx Testing vs Treatment as Usual Study Design

GUIDED Trial of PGx Testing vs Treatment as Usual Efficacy Outcomes

GUIDED Trial of PGx Testing vs Treatment as Usual Subset Analysis

Practical Application of PGx Testing

Metabolizer Phenotypes

Examples of Pharmacogenomic Decision Support Tools in Psychiatry

Differences in PGx Testing Platforms

Clinical Utility of PGx Testing

Potential for Improving Utility of PGx Testing

Cost-Effectiveness of PGx in Psychiatric Disorders

Does PGx Have a Role in Psychiatric Practice?

Does PGx Have a Role in Psychiatric Practice? (cont)

PRIME Care Study of PGx Testing in US Veterans Study Design

Personalized Medication Decision Factors

Conclusions

Abbreviations

Abbreviations (cont)